Maze Therapeutics (NASDAQ:MAZE) Receives Buy Rating from HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $110.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 291.60% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday. Citigroup began coverage on Maze Therapeutics in a report on Wednesday. They issued a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Wedbush reissued an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Trading Down 1.0%

MAZE opened at $28.09 on Thursday. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -11.15 and a beta of 2.17. The company’s 50 day simple moving average is $27.18 and its two-hundred day simple moving average is $29.17. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Analysts expect that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at approximately $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 191,459 shares of company stock valued at $5,263,539 in the last three months. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth $133,502,907. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the second quarter valued at about $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics in the second quarter valued at approximately $104,525,000. Jupiter Topco LLC acquired a new stake in Maze Therapeutics in the second quarter valued at $101,764,000. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth $41,435,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.